Joincare details Q3 2025 performance, strategic growth initiatives

Joincare Pharmaceutical Group Industry hosted its third-quarter 2025 investor briefing on November 25, 2025, addressing questions regarding its operating performance and financial metrics. Key company representatives, including chairman Mr. Zhu Baoguo and chief executive Mr. Lin Nanqi, were in attendance.

The company is actively advancing its international registration efforts, having established subsidiaries in the Philippines and the Netherlands to build local registration, compliance, and sales systems across Southeast Asia and the EU. Several inhalation formulations are progressing through multi-regional registrations, with manufacturing bases cleared by GMP inspections in multiple Southeast Asian countries. Furthermore, its subsidiary, Livzon Pharmaceutical Group, has secured market approval for recombinant human chorionic gonadotropin in Pakistan and Uzbekistan and initiated registration for Semaglutide injection in Pakistan and Apremilast sodium injection in Malaysia. The company also confirmed its commitment to BD collaborations, including an IL-17A/F monoclonal antibody product.

Joincare is diversifying its portfolio, with over 10 Class 1 innovative drugs in development in the respiratory field. The most advanced, Mapacidevir capsules for influenza treatment, is in the late stages of review, with commercialization preparations underway. The company also reported that its Tobramycin inhalation solution (Jian Ketuo) continues to grow well in the second half of the year, although reimbursement policies currently limit its sales. Livzon has also introduced a novel influenza vaccine, which is in Phase I clinical trials.